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Abstract
In the presented study short sequences of the Aβ peptide where simulated. Aβ
oligomers are known to be the main reason for Alzheimer’s disease. Therefore,
not only simulations with the 16KLVFFAE22 and the 30AIIGLM35 Aβ fragments,
known to aggregate from in vitro studies, are carried out, but also ligands known to
inhibit aggregation are simulated. The results show that one of the ligands prevents
beta-sheet formation which is a critical step for fibril formation, via competition for
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From in vivo studies it is known that protein aggregates are related to many dis-
eases (e.g. Alzheimer’s disease)[1]. There are also many in vitro studies that show
the toxicity of oligomeric aggregates[2]. Unfortunately, the majority of experimental
studies can not reveal driving forces on a molecular level. Therefore, MD simula-
tions are applied that give us the opportunity to learn more about critical motions
and underlying forces in proteins. Knowledge of these forces can also help in drug
development. If one is capable of investigating forces that drive aggregation and
the way existing drugs hinder aggregation, it might be possible to develop highly
effective drugs.
1.2. The Aβ peptide
The Aβ peptide is related to Alzheimer’s disease (AD) in vivo[3]. Therefore it is of
interest to carry out research on the aggregation behaviour of this peptide.
1.2.1. Formation and structure
In vivo the Aβ peptide is derived from the Amyloid precursor protein (APP)[4]. APP
itself maps to chromosome 21[5], a reason for increased occurrence of Alzheimer’s
Disease (AD) in down syndrome (trisomy 21) patients[6]. The APP is cleaved by
either the α-secretase or the β-secretase[7]. This process yields different interme-
diate products, both further processed by γ-secretase[8]. The cleavage product of
APP by β-secretase and γ-secretase is the Aβ peptide that consists of 39-43 amino
acids[9]. Mutations on APP are found to increase Aβ production in vivo[10]. In
order to come up with therapeutic strategies for e.g. AD, it is important to know
about the role of Aβ in humans. However, little is known about the actual role of
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(a) Structure of soluble Aβ1−42 resolved by
NMR (PDB ID 1IYT)[13].
(b) Model of Aβ1−40 in an aggregated
state. Based on solid-state NMR
with additional constraints from elec-
tron microscopy[14].
Figure 1.1.: Misfolding of the Aβ peptide is suggested to lead to conversion from the
natural helical structure to a beta-sheet aggregated state.
this particular peptide. Recent studies showed that it has antimicrobial function[11].
Other studies provided evidence for a role in neuronal transfer[12].
In the natural state the Aβ peptide consists of two helices linked via a beta-turn[13].
It is proposed that misfolding might lead to the exposure of regions that are known
to form aggregates[1]. It was demonstrated that different sequences in the Aβ1−42
can form aggregates on their own, leading to polymorphic structures[15]. A common
motif along these polymorphic structures is the dry steric zipper interface between
the peptides[15]. This means that the peptides form a beta-sheet that excludes the
solvent from its inner interface. Resolved full length Aβ structures show that parts
of the peptide are found in these interfaces (see figure 1.1b). As many of these
structures stack together, amyloid fibrils are formed. Their inner part consist of a
highly organized beta-sheet stack called amyloid spine or backbone. This motif was
found for the different types of amyloid state related diseases[16].
It is mandatory for MD studies to concentrate on smaller systems, known to behave
like the full length system as suitable model systems. This reduces computational
efforts and therefore provides the chance to get access to larger timescales of simula-
tion. As it is known from former studies that a variety of short sequences of the Aβ
peptide form aggregates on their own[15, 17] and that they can also be inhibited[18]
it is of particular interest to focus on them. In the presented study the focus is on
16KLVFFAE22 and on 30AIIGLM35.
2
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Figure 1.2.: Mechanisms of toxicity proposed for oligomeric aggregates of the Aβ-
peptide [19]
1.2.2. Mechanisms of toxicity
The suggested mechanisms of toxicity of the Aβ peptide involve the oligomeric state
as a key player[20]. Neither full size plaques nor monomers play an essential role
in toxicity[21]. It was found that Aβ1−42 seems to be the more toxic form because
it is more prone to undergo aggregation[22]. This becomes especially evident from
familial types of Alzheimer’s disease (FAD) in which increased Aβ1−42 production is
found[23]. Other studies demonstrate that the Aβ1−42 to Aβ1−40 ratio is crucial[24].
The importance of this ratio is also indicated by studies looking at the correlation
between AD and down syndrome[25].
Three different mechanisms of toxicity have been proposed (see figure 1.2). Inter-
actions between the oligomers and the membrane lead to membrane thinning[26,
27]. The membrane peptide interaction may also lead to cation selective pore
formation[28]. In addition, Aβ oligomers are able to interact with already exist-
ing Ca2+ channels[29]. All of these changes in the membrane lead to disruption of




As AD gets more abundant in the aging society, it is not astonishing that a drug to
cure AD is one of the most urgently pursued goals of not only the pharmaceutical
industry but also of research teams all over the world. On the one hand drugs are
known for “symptomatic approaches for the treatment of AD” and on the other
hand “disease-modifying approaches for the treatment of AD”[30]. Here the focus
will be on the second type.
Different stages in the process of amyloid plaque formation have been identified to
discover drugs. As described previously APP is cleaved to Aβ. One step in this
cleavage is done by β-secretase. There are different types of β-secretase known
as BACE-1, normally found in the brain, and BACE-2 commonly found in other
organs[31]. As BACE-1 is found mainly in the brain, it seems to be the more im-
portant for β-secretase in neurons[32]. As β-secretase does not alter other pathways
of APP processing it causes the least intervention on the side of production. But
it still has to be taken into account that the function of Aβ is mostly unknown.
Therefore changes in production of Aβ might have unwanted side effects.
The same arguments hold for an alternative strategy to reduce the production of Aβ
by blocking the γ-secretase. In addition the problem arises that not only the preform
of Aβ is a substrate for this enzyme complex, but also other proteins (e.g. Notch
receptor)[33]. Therefore not only blocking the γ-secretase is considered a suitable
way for drug development[3, 34, 35]. As mentioned before the most crucial value for
plaque formation is the value of Aβ42/Aβ40. Therefore methods have been developed
to alter γ-secretase specifically to produce sorts of Aβ other than Aβ42[36].
As a third possibility a change in α-secretase might alter the pathway. Elevated
activity of α-secretase might decrease Aβ production because of competition with
β-secretase for the cleavage of APP[37]. Here the major difficulty is to rise the con-
centration of α-secretase specifically in the compartments where APP is cleaved[38].
As an additional therapeutic strategy immunization via injection of aggregated Aβ
plaques[39] was tested successfully as well in in mouse models[40] as in in vivo hu-
man studies[41, 42].
In this study the focus will be on a strategy not mentioned yet. This is the alteration
of Aβ oligomers, the main reason for AD[43]. Once more two different approaches
exist. On one hand oligomeric Aβ can be reduced, at the expense of encouraging
formation of fibrillar forms[44]. This was shown to improve cognitive function of
Aβ overproducing transgenic mice[45]. Or, and this is the main goal of the pre-
4
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sented study, to find inhibitors of the aggregation as already extensively studied by
others[10, 18, 46–48]. With both methods shown to have effect[44, 49], it would be
better to inhibit aggregation. The problem in speeding up the aggregation is once
more the probable loss of function for the Aβ with unknown effects.
1.3. MD simulation
In the field of structural biology different experimental methods have been developed
to study biological systems in atomic detail (e.g. Nuclear Magnetic resonance-NMR,
X-ray crystallography). But the methods do have their disadvantages; e.g. for X-
ray crystals are required and therefore the study of dynamics is difficult. Even with
methods like NMR, where time resolution is provided, we find critical motions to
be often below its time- and sometimes below its spatial resolution[50]. Therefore
computer simulations have been developed. The most frequently used approach is
molecular dynamics (MD) simulation. It can be applied to study molecular motions
like protein dynamics in detail[51]. On length scales as short as in proteins not
only classical mechanics but also quantum mechanics has to be considered. At
the beginning this has been done by developing methods to solve the Schrödinger
equation. But this is a method limited to only small systems of a few hundred
atoms[52]. Instead of solving the Schrödinger equation, MD uses so called force fields
(FF) to simulate dynamics of molecules. These FF are used from MD programs and
contain the potentials of forces that are applied classically by these programs. One
of the most frequently used programs for MD simulations is GROMACS[53–55].
In classical MD simulations the following assumptions are applied in addition to the
force field assumption.
Born-Oppenheimer approximation In the Schrödinger equation the motion of
nuclei and electrons have to be solved simultaneously. The idea of the Born-
Oppenheimer approximation is to separate these parts from each other. This is
possible due to the different timescales of motion (e.g. from the point of view of an
electron the nuclei are not moving). Electrons move much faster due to their lower
mass. This gives separated wave functions which still have to be solved.
In biophysics the interest is upon the motion of the nuclei. Therefore in the force
field approach the electron part of the wave function is described by bonded inter-
actions as well as Van der Waals interactions.
5
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For the nuclei an additional simplification needs be made.
Classical description of nuclear dynamics In the force field approach all motions
are described via a potential term that gives forces as in the classical mechanics. The
parameters for this potentials are given in the force field. Being able to calculate
the forces a velocity-verlet algorithm is applied to integrate the equations of motions
numerically.
1.3.1. Force fields
Current biomolecular force fields (FF) in use are for example the Amber[56] FF
and the Charmm[57] FF. Recent studies show that most of the FFs can reproduce
experimental data in a reliable way[58]. The main difference from the technical part
between them is the way how to derive the parameters the FFs consist of. But what
they have in common is their way to describe the atomistic world. MD simulation
programs use the potentials given in the FFs that are classified into (i) bonded




= Vbonded + Vnon-bonded (1.1)
That means a molecule can either interact with another particle because they are
(i) connected via a chemical bond or (ii) they are not connected but exert a long
range force like a Coulomb force. Restraints are more artificial and can be applied
arbitrarily to any selection of atoms to hold them into a certain relative position.
Bonded interactions
Bonded interactions are interactions of a fixed neighbor list. Bonds are the represen-





In this potential x is the current position of one molecule relative to another. This
formula shows the need to determine for each pair of molecules an equilibrium state
x0 and a force constant κ. These constants are defined by the FF parameters. In
6
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(a) bond (b) angle (c) dihedral
Figure 1.3.: Illustration of the different bonded interactions.
the FF 3 different types of bonded interactions are used. They are named after the
restrictions put upon the atoms by them.
Bond potential In the bond interactions 2 atoms are involved. The interaction can
be imagined to be due to a spring. Figure 1.3a explains the alternative name bond
stretching potential. In this case the parameter x0 is the distance between the two
atoms in equilibrium. κ is a spring constant as known from classical mechanics. It
should be mentioned, that even if this potential is the most common there are other
potentials for 2-body interactions available. There even exist anharmonic potentials
(e.g. Morse potential).
A frequently used approach to bonds is to constrain the bonds, meaning that the
bonds can not stretch. This is done using algorithms like LINCS[59] or SHAKE[60].
Angle potential In the angle potential 3 atoms are involved. This interaction is
demonstrated in figure 1.3b. Here the given x0 is the angle between the two bonds
formed by the three atoms at equilibrium. The motion induced by this potential is
a vibration around the equilibrium state.
Dihedral potential The dihedral potential restricts four atoms into two plains with
a certain angle (dihedral angle) to each other. This is demonstrated in figure 1.3c.
The two plains are i,j, k and j, k, l. The angle in equilibrium is measured from the
so called cis state where i and l are on the same side.
Non-bonded interactions
The partners of a non bonded interaction are not given in a fixed list as it is in
bonded interactions, but in a list that is updated after a predefined number of
7
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steps. All non bonded potentials are pair additive. The main potentials of the non-
bonded interactions are the Lennard-Jones or the Buckingham potential as well as
the Coulomb potential.







Here the parameters c1 and c2 have to be determined for every pair of atoms sepa-
rately. Therefore the FFs have a list of possible combinations where the constants
can be looked up. The Lennard-Jones potential describes the interaction of the
electron cloud. As the electron cloud can be polarized it has an attractive 1/r6
term. On the other hand for short distances the pauli exclusion principle prevents
the atoms from getting too close. Is is modelled by the repulsive 1/r12 term.
Coulomb Coulomb interactions are computationally the most expensive in the
simulations. As the range of these interactions is long-range, it can not be neglected
at large distances, lead to a computational cost of O(N2). This effort is reduced by
the so called particle mesh ewald[61] method. It uses the periodicity of the system
to calculate the forces in the Fourier space, leading to a computational effort of
O(N · logN).
Deriving parameters
Even if the way how to derive the FF parameters differs, they have basic strategies
in common. Quantum mechanical calculations are carried out to get a first set
of parameters. These parameters are further optimized via specific experimental
setups. Some force fields are optimized to reproduce specific structural patterns at
the expense of others (e.g. some prefer helical structures before beta-sheets). This
leads to the problem that not all force fields are equally suitable to study a given
problem.
1.3.2. GROMACS algorithms
Without going too much into detail a short introduction to algorithms applied by
GROMACS is given here. GROMACS is a simulation software to use the informa-
tion provided by the FFs to run a MD simulation. The simulated system is prepared
8
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in a suitable box. These boxes have most commonly periodic boundary conditions
(pbc). Pbc are used to minimize boundary effects. Therefore the simulated box
is considered to be replicated at every boundary. To this box an external pressure
and temperature coupling is applied. This is needed because by solving the equa-
tions of motion we are naturally in a microcanonical (NVE) ensemble. Physiological
conditions are normally at constant temperature and constant pressure. Therefore
the coupling algorithms are applied to get into the isothermal-isobaric (NPT) en-
semble. For both types of coupling different algorithms are available (e.g. velocity
rescaling[62] for temperature and Parrinello-Rahman[63] for pressure). In addition
GROMACS provides a variety of tools to analyze the files created during the MD
simulation.
1.3.3. Limitations
Due to the applied assumptions, limitations are encountered in this approach that
are not present in the quantum mechanical calculations. For example, if a bond is
described via a harmonic potential it can never break. Nor is there a possibility
to form new bonds. Therefore chemical reactions can not be described via the FF
approach.
Furthermore due to numerical integration errors might occur if the integration
timestep is chosen too large.
For a further introduction on MD implementation and methodology see[64].
1.4. Ligands
From in vitro studies performed by C. Griesinger et al. (NMR-based Structural
Biology, Max-Planck-Institute for Biophysical Chemistry) two small molecules (for
structure see figure 1.4) that can inhibit full length Aβ aggregation are known.
For the first ligand two different protonation states of the nitrogens are known, pop-
ulated 1:1. One of the nitrogens is always protonated while the other is not. This is
a drawback as in MD studies the protonation state must be defined at the beginning
of the simulations. Therefore to simulate the system as close as possible to an in
vitro experiment, the ligands are always simulated as pairs with one of them being
in one protonation state while the other is in the other protonation state.
9
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(a) Ligand 1 (b) Ligand 2
Figure 1.4.: The ligands simulated in the system.
For the second ligand the protonation state is unambiguous. This is one of the
reason to put the focus on the second ligand.
Another important difference to the first ligand is the charge. While the first ligand




An overview of the simulated systems is given in table 2.1. The steric zipper peptides
with sequences 16KLVFFAE22 and 30AIIGLM35 were simulated with (3 simulations
each) and without ligands (1 simulation for each peptide ligand combination, expla-
nations to the ligands are given in section 1.4), in the Amber FF as well as in the
Charmm FF. In addition the simulations without the ligands are also carried out
with preformed beta-sandwich structures (instead of 16KLVFFAE22, 16KLVFFA21
was used).
The 16KLVFFA21 (instead of 16KLVFFAE22) peptide was also simulated with a sin-
gle ligand of type 2 (5 simulations) using the Charmm FF. Furthermore one of the
preformed structures of 16KLVFFAE22 is chosen (with intermediate stability) after
100 ns. This structure is the basis for a new simulation with 12 additional ligands
of type 2.
2.2. Starting structures and topologies
In order to impose no bias to the aggregation the following protocol was applied to
set up the simulations. Alternatively, the starting structures of monomeric peptides
were created using PYMOL[65]. To these structures CONCOORD[66] was applied
to generate an ensemble of 1000 randomly twisted peptides. CONCOORD only
considered topological constraints.
The preformed structures were constructed based on crystal structures from the
PDB. For Aβ16−21 the three different forms 2Y2A, 3OW9, 2Y29 and for Aβ30−35
2Y3J were considered[15].
The topologies for the ligands in the Amber FF have been created using antechamber[67]
(Creation of structure and topology was carried out by Vytautas Gapsys (Depart-
11
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Force Field Peptide (#, conc.) Ligand (#, conc.) Information
Amber & Aβ16−22 × 3 simulationsCharmm (12, ∼20 mM)
Amber & Aβ30−35 × 3 simulationsCharmm (12, ∼20 mM)
Amber & Aβ16−21 × preformed,Charmm (12, ∼20 mM) 3 different formes
Amber & Aβ30−35 × preformedCharmm (12, ∼20 mM)
Amber & Aβ16−21 Ligand 1 & 2 †Charmm (12, ∼20 mM) (12, ∼20 mM)
Amber & Aβ30−35 Ligand 1 & 2 †Charmm (12, ∼20 mM) (12, ∼20 mM)
Charmm Aβ16−22 Ligand 2 5 simulations(12, ∼20 mM) (1, ∼1.7 mM)
Charmm Aβ16−21 Ligand 2 continued preformed(12, ∼20 mM) (12, ∼20 mM) after 100 ns
Table 2.1.: Overview of the simulated systems. ×: simulation systems without lig-
ands, †: no additional information
ment of Theoretical and Computational Biophysics, Max-Planck-Institute for Bio-
physical Chemistry)). In addition sigma holes[68, 69] were applied to the bromine
atoms.
Ligand topologies compatible with the Charmm FF were created using the Swiss-
Param fast force field generation tool[70]. An ensemble of 100 ligand structures in
a random conformation was generated using tCONCOORD[71], considering only
topological constraints.
For all systems, monomeric peptides and ligands are chosen randomly from the pre-
viously calculated ensembles and placed randomly in a cubic box of 1000 nm3. In
addition explicit solvent and ions in a concentration of 0.15 M were added. The
protonation states for all systems were at pH 7.
2.3. MD Setup
All MD simulations were carried out using GROMACS version 4.5.5[53–55]. The
force fields used were the Amber ff99SB?-ILDN[56] and the Charmm36[72] together
with the TIP3P water model[73]. All bonds were constraint using LINCS[59]. The
velocity-rescaling[62] algorithm was applied to couple the simulation system to an
12
2.3. MD Setup
external heat bath with a temperature of 300 K using a time constant of τ = 0.1 ps.
For pressure coupling the scheme of Parrinello-Rahman[63] was used to hold the
system at a pressure of 1 bar. Initial velocities were taken according to a Maxwell-
Boltzmann distribution at 300K. All simulations were carried out with periodic
boundary conditions applied to the simulation box. Prior to the simulations, energy
minimization was applied.
2.3.1. Amber FF
Virtual sites[53] were used to increase the time-step to 4 fs while maintaining energy
conservation. The neighbor list was updated every 3 steps. The neighbor list cut-off
was chosen as rc = 1.0 nm. For further electrostatic forces Particle Mash Ewald
(PME) was applied with a cut-off of rc = 1.0 nm[61]. The VdW-type was chosen to
be Switch with a cut-off of rc = 1.0 nm and a total cut-off of 1.2 nm. In the Amber
FF a time constant of τ = 1 ps was applied.
2.3.2. Charmm FF
The time-step was set to 2 fs. The neighbor list was updated every 10 steps. The
neighbor list cut-off was set at rc = 1.4 nm. Here also PME was applied with a
cut-off of rc = 1.4 nm[61]. For VdW-type a cut-off was used with a cut-off range of
rc = 1.0 nm. For the Charmm FF a time constant of τ = 4 ps was used.
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3.1. Association
It is known that the Aβ segment 16KLVFFAE22 is an aggregating sequence[15]. This
segment is simulated in the Charmm FF as described in chapter 2. For all three
simulations carried out (in the figures referred to as trails) aggregation is found for
this peptide. In figure 3.2 the clustering behavior is plotted as a function of time.
Here peptides closer together than 0.4 nm are considered to form a cluster. If an
additional peptide is within a distance of 0.4 nm of a peptide in a cluster, this addi-
tional peptide is considered a member of the same cluster. The cluster assignment
is color coded in the figure. At the beginning the monomers almost immediately
start to aggregate. The aggregation pathway is through a variety of oligomeric in-
termediates.
After 100 ns the majority of the peptides are part of an aggregate. Some individual
peptides can still be found in a monomeric state or in independent clusters, but the
majority can be found within one cluster. In the later progress, patterns of smaller
aggregates can be found for short times (e.g. at the end of trail 1).
The fast growth in a variety of smaller oligomers (later forming one single clus-
ter) is contrary to the mechanism suggested by the seeding hypothesis, in which the
major barrier for aggregation is suggested to be the formation of a seed [74, 75]. One
reason might be that for the full length Aβ it is necessary to have a sequence acces-
sible that can form oligomers. These sequences need to be accessible simultaneously
for all interacting peptides at the time of their encounter. Because of the fewer
number of residues in this studied fragment this is always given in an encounter of
the examined peptide.
The pattern of smaller aggregates in the later part of the simulations arises due
to internal reformation. By visual inspection of the trajectories a disassembly was
not observed. The clustering algorithm used for figure 3.2 however shows oscilla-
15
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(a) At the beginning (b) After 500 ns
Figure 3.1.: The 16KLVFFAE22 peptide simulated in the Charmm FF. At the be-
ginning 12 peptides are distributed randomly in a box. During the
simulation they form a cluster and arrange into beta-sheets.
Figure 3.2.: Clustering behavior over time of 16KLVFFAE22 in the Charmm FF. The
same color represents the belonging to the same cluster. A peptide is
defined to be in a cluster if the distance to a peptide in the cluster is
less than 0.4 nm.
16
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Figure 3.4.: The clustering behavior of the 16KLVFFAE22 peptide in the Amber FF.
For further explanation see figure 3.2.
tory behavior, suggesting transient disassembly. This may be due to the applied





cut-off distance in the cluster definition. For fur-
ther simulations a new definition of clusters with
another distance should be considered to create
the cluster figures, matching the behavior seen
by visual inspection.
The same simulations are carried out with the
Amber FF to find out how differences in the force
fields affect the aggregation behavior. This is im-
portant to separate effects that are exclusively
found due to force field parameters.
In the Amber FF the aggregation is frequently
limited to few peptides (see figure 3.4). These
aggregates are mostly unstable. Only in one of
the simulated systems a larger aggregate forms
that appears to be stable (at the end of trail 2 in
figure 3.4). In other simulations (e.g. trail 3 af-
ter 450 ns) larger aggregates form as well. But in
the contrast to the simulations in the Charmm
FF they disassemble rather fast.
Comparing the aggregation in the Amber FF to
the previously described behavior in the Charmm FF, a difference in speed and
frequency of aggregation is observed. (compare figures 3.2 and 3.4). While clusters
in the Charmm FF, once formed, rarely start disassembling and mostly reform, this
17
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Form 1 (PDB: 2Y2A)
Monomer Cluster1 Cluster2 Cluster3 Cluster4 Cluster5












Form 3 (PDB: 2Y29)
Monomer Cluster1 Cluster2 Cluster3 Cluster4 Cluster5
Figure 3.5.: The clustering behavior of preformed structures of the 16KLVFFA21 Aβ
segment simulated in the Amber FF. The starting structure is a dry
steric zipper consisting of 12 peptides. The structure is a fragment
from a crystal structure. For further explanation see figure 3.2.
behavior is not observed for the simulations performed with the Amber FF, where
clusters frequently form and disassemble.
Thus, for this sequence, the Charmm FF shows a greater aggregation-propensity
than the Amber FF.
In addition, simulations have been carried out with preformed structures taken
from crystal fragments[15]. These structures are simulated in the same setup as
used for the randomly distributed peptides. The observed behavior of these simula-
tions is distinct among the different initial structures. While the simulations carried
out in the Charmm FF do not show disassembly for any of the starting structures,
in the Amber FF one of the structures disassembles to the major part while one
stays aggregated(see figure 3.5).
This might suggest that in the Amber FF the initial arrangement of the aggregate
is important. For the assembly simulations the behavior of the preformed structures
18
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implies that the stable aggregate first has to be reached from the random starting
structure. The variety of aggregates described by Colletier et al.[15], of which some
seem to be unstable, may explain the aggregation behavior observed in the Amber
FF: If unstable aggregates form in the simulation with the randomly distributed
starting structure they will disassemble again.
To quantify this behavior it would be of interest to compare the spontaneously
formed structure that was found to be stable in the Amber FF with the stable
pre-formed aggregate using a Root Mean Square Deviation (RMSD) analysis. The
provided hypothesis would be supported if the RMSD of the aggregated structure
formed in the simulations with a random starting configuration would be smaller for
the preformed structure found to be stable, than to structures found to be unstable.
The disassembly of preformed structures was not observed in the Charmm FF. For
all three simulated preformed structures (2Y2A, 3OW9 and 2Y29) exclusively re-
laxation but no disassembly was observed.
These findings lead to the choice of the Charmm FF as the FF for the majority of
the simulations to be carried out to study aggregation, and the putative effect of
inhibition.
19
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Figure 3.6.: Secondary structure as a function of simulation time for 16KLVFFAE22
in the Charmm FF calculated by DSSP[76]. The vertical coordinate rep-
resents the residue number (1 is the first residue of one of the peptides,
8 is the first residue of the next peptide, and so on). The secondary
structure is color coded.
3.2. Secondary structure
As a second observable the secondary structure is of interest. It is known that the
amyloid fibrils grow due to the formation of a backbone consisting of beta-sheets[16].
The used fragment is known to form such a beta-sheet in vitro[15].
For the simulations in the Charmm FF the secondary structure is inhomogeneous
throughout the different simulations (see figure 3.6). While the first simulation shows
a high beta-sheet content, the other simulations do not. In the second and third
simulation other secondary structure elements, like bend and turn, are appearing
more frequently. This large inherent spread indicates that it will be challenging to
derive statistically significant differences due to e.g. FF or inhibition effects. Con-
trary to the aggregation behavior, the formation of beta-sheets can also be found in
a later point of simulation.
What is of special interest is the difference between the simulations. Comparing the
secondary structure to the aggregation behavior a correlation between beta-sheet
content and stability is apparent. As beta-sheets are very rigid structures due to
intra-chain hydrogen bonds it is evident that the rearrangement of them is limited.
Therefore it gets apparent why the first simulation shows a higher packing (see figure
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Figure 3.7.: The secondary structure elements over time for the16KLVFFAE22 pep-
tide in the Amber FF. For further explanation see figure 3.6.
3.2) than the others do. From the rearrangements it is suggested that the simula-
tions have not reached the absolute minimum of the free energy landscape yet. This
should be the fully aggregated state[77], most probably a dry steric zipper as found
in in vitro studies[15].
The additional simulations carried out in the Amber FF also show a variety in sec-
ondary structure elements. Beta-sheet formation was obsered in all simulations. In
the second simulation the beta-sheet content is much higher than in the other sim-
ulations in which other secondary structure elements, like bend and turn, are more
common.
Compared to the Charmm FF none of the observed differences are statistically sig-
nificant. However it is apparent that in the Amber FF the secondary structure
forms more slowly than in the Charmm FF. But this can also be exclusively due to
statistics and is not necessarily due to systematical reasons. This is quite surprising,
seeing that the aggregation behavior differs significantly in the two FF.
Comparing the aggregation behavior more closely to the secondary structure, it
seems that aggregates once formed in the Amber FF, do adopt a beta-sheet sec-
ondary structure much faster than they do in the Charmm FF.
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3.3. Changes due to ligand interaction
To see the effect of the ligands on the aggregation, the ligands are simulated in a
ratio of 1:1 with the peptides (for further explanations see section 2). Focusing on
the aggregation (see figure 3.9a) the simulations carried out with the first ligand
show two separated clusters which unify in the later simulation. In the case of
the second ligand the simulation shows a pathway of growth through encounters of
dimers and a rapid growth to the full length structure (an example structure from
the simulations is shown in figure 3.8). For both systems all peptides and ligands
form a single aggregate after 100 ns.
The aggregation goes through the aggregation of ligands with peptides as well as
ligand-ligand and peptide-peptide aggregation. Neither of them seems to be pre-
ferred.
Comparing this to the aggregation of 16KLVFFAE22 without ligands (see figure 3.2)
these seems to be not significantly different. In addition the differences between
the simulations with the two ligands might be due to limited statistics and not sys-
tematic. To validate this further, additional statistics (simulating the same system
more frequently) would be necessary.
Looking at the secondary structure a very different effect of the two ligands was
found. For the first ligand the secondary structure consists mostly of beta-sheets.
These form during the simulation with the ligands in the same cluster. Residues
that are not within a beta-sheet are mostly adopt coil conformation. For the second
ligand a variety of secondary structure elements like turns and bend is observed, but
beta-sheets are almost not forming. Only between 220 and 300 ns, a beta-sheet was
observed.
The change of secondary structure seems to be significant enough to suggest an effect
due to the ligands. Especially looking at the difference between the secondary struc-
ture seen for the two ligands, an effect is probable. The first ligand seems to prohibit
formation of secondary structure elements like turns and coil while encouraging the
growth of beta-sheets and for the other parts remaining in coil. The exact oppo-
site effect seems to be introduced by the second ligand. Here the arrangement into
turns and bend seems to be encouraged while the growth of beta-sheets is prevented.
Interaction energies might elucidate the difference between the simulations with the
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Figure 3.8.: Aggregate of Aβ segment 16KLVFFAE22 and ligand 2. Shown is a con-
figuration reached after 420 ns of simulation. The setup were randomly
chosen starting positions for ligands and peptides.
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(a) Clustering behavior. Number 13 to 24 are the ligands.
(b) Secondary structure
Figure 3.9.: The 16KLVFFAE22 peptide simulated in the Charmm FF, with addi-
tional ligands. The ratio of ligands to peptides is 1:1. Compare to
figures 3.2 and 3.1a For further information see figures a) 3.2 and b)
3.6.
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(a) peptide-peptide interaction energy with-
out ligands
(b) peptide-peptide interaction energy with
ligands
(c) ligand-peptide interaction
(d) coulomb energy for ligand-peptide inter-
action
Figure 3.10.: The 16KLVFFAE22 peptide simulated in the Charmm FF. Shown is the
change of energy over time. The energies have been calculated using
the g_energy tool from the GROMACS software package[53–55]
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different ligands as well as between the simulations with the ligands and without.
Without ligands a significant drop of energy of the peptide-peptide interaction is
observed for all simulations (see figure 3.10a). In all of the simulations the energy
drops around 2500 kJ/mol during the first 450 ns.
For simulations with ligands the energy starts at the same value as in the case with-
out ligands. The simulation of the first ligand does not show a significant difference
in the peptide-peptide energy from the simulated systems without ligands (see figure
3.10b). For the second ligand the energy of the peptide-peptide interaction changes
less from the beginning of the simulation to its end. This difference between the
simulations without ligands and with ligands is around 2000 kJ/mol.
Additionally, ligand-peptide interactions have been analyzed for the simulations with
ligands (see figure 3.10c). Here a large change in energy between the starting config-
uration and the end configuration is visible for the second ligand. The first ligand,
almost starting at the same energy, does not show a change as significant as the sec-
ond ligand. Here, the differences of the peptide-ligand interaction energy is around
2000 kJ/mol. Interestingly, the same pattern was observed looking only at coulomb
interactions of the peptides with the ligands (see figure 3.10d). This change in en-
ergy shows again differences between the first ligand and the second one. It therefore
seems as if the change in the peptide-peptide energy observed for ligand 2 is due to
the compensating energy of ligand-peptide interactions.
Large differences between the ligands were found although the ligands are quite
similar. The main difference between them is the charge carried by the second
ligand. This leads to the major difference as indicated by the coulomb interac-
tion energy. 16KLVFFAE22 carries two charged residues. These are the positively
charged lysine(K) and the negatively charged glutamic acid(E). In addition the N-
and C-termini carry charges.
To determine the effect of the charged residues, a suggested analysis would be the
determination of the residues mainly interacting with the peptide.
As simulations with another peptide have already been carried out, this might
also be a possibility to find out the effect of charged interactions. This is done for
the 30AIIGLM35 Aβ segment, with neutral side chains.
The secondary structure of the simulations without the ligands is inhomogeneous.
The first simulation adopts a large number of beta-sheets, while the other simula-
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(a) simulations without ligands (b) simulations with ligands
Figure 3.11.: Secondary structure of 30AIIGLM35 in the Charmm FF. For the simu-
lations with ligands the upper graph shows the behavior with the first
ligand, the lower one shows ligand 2. For further information see figure
3.6
tions adopt rather other conformations (see figure 3.11a).
While the simulation with the first ligand shows a low propensity to form beta-
sheets, the simulations with the second ligand do not show beta-sheets but only
beta-bridges.
Although this pattern would be consistent with the change of peptide-peptide inter-
action as previously mentioned, the change due to the ligand is not significant. Both
of the secondary structures found in the simulations with the ligands are within the
range of diversity found for simulations without ligands.
The peptide-peptide interaction energy drops for this segment as aggregation pro-
gresses in the case without any ligands (see figure 3.12a). This is comparable to
the 16KLVFFAE22 peptide. But for 30AIIGLM35 the interaction seems to be more
inhomogeneous than for 16KLVFFAE22.
The peptide-peptide interaction energies for the simulations with ligands (see fig-
ure 3.12b) decrease during the simulation. While this was also found for the other
peptide, the difference is that both energies drop almost equally. No significant
difference between the two ligands is observed in the energies.
The ligand-peptide interaction energy (see figure 3.12c) decreases over time for both
ligands. For both ligands it seems to reach almost an equilibrium state with ligand
2 showing a strong interaction. An energy difference of around 1500 to 2000 kJ/mol
between the ligands is observed at the end of the simulation. This difference is sim-
ilar to the difference found for the other peptide: A similar drop in coulomb energy
27
3. Results and discussion
(a) Energy of peptide-peptide interactions
without ligands.
(b) Energy of peptide-peptide interactions
with ligands.
(c) Energy of ligand-peptide interaction.
(d) Coulomb energy of ligand peptide inter-
action.
Figure 3.12.: Energy of 30AIIGLM35 in the Charmm FF. For further information see
figure 3.10.
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as in the case of the 16KLVFFAE22 peptide is observed (see figure 3.12c).
The observed interactions lead to the suggestion that the majority of interaction
is due to coulomb energy. The similarity in the behavior of the peptides with and
without charged side chains suggests that the charged second ligand does not inter-
act with the charged side chains but rather with the charged termini.
It seems as if the interaction with termini, that is suggested as charged interaction
for the second ligand with the 30AIIGLM35 segment, does not change the energy of
peptide-peptide interaction. This suggests that in the process of beta-sheet forma-
tion the charged termini do not play a major role. The coulomb interactions of the
first ligand with the 16KLVFFAE22 peptide has a change of energy comparable to
the ligand free case, while the peptide-peptide interaction seems to be reduced. This
leads to the suggestion that the interaction of the ligand with this peptide might be
predominantly with the charged side chains.
As the beta-sheet structure is formed by hydrogen bonds it is of interest to ana-
lyze on the hydrogen bond energies (see figure 3.13). In the simulations with the
16KLVFFAE22 peptide a drop of hydrogen bond energy between the peptides is ob-
served upon aggregation. The drop of hydrogen bond energy for peptide-peptide
hydrogen bonds is also observed in simulations with this peptide and the first lig-
and. For simulations with the second ligand and this peptide the hydrogen bond
energy between the peptides is less pronounced. The peptide-ligand hydrogen bond
energies in the simulations with 16KLVFFAE22 and the ligands shows the opposite
trend. For the first ligand the interaction is weaker than for the second ligand.
The change in the hydrogen bond energies suggests competitive inhibition by the
second ligand for hydrogen bonds between the 16KLVFFAE22 peptides.
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Figure 3.13.: Hydrogen bond energies for the 16KLVFFAE22 peptide with and with-
out ligands simulated in the Charmm FF.
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4.1. Conclusions
In the presented study simulations with the Aβ fragments 16KLVFFAE22 and 30AIIGLM35
were carried out. Furthermore, simulations with a combination of 12 peptides of
one type and small molecules known to inhibit full length Aβ aggregation were per-
formed. To reduce the bias introduced through force field parameters the two FF
Amber and Charmm were applied to some of the simulations.
From the simulations of 16KLVFFAE22 in the Charmm FF no prevention of aggre-
gation was observed due to the addition of ligands. Instead, a change of secondary
structure through the ligand interaction was observed. While the mechanism of
interaction stays mostly unrevealed for the first ligand, the charge of the second
ligand probably is the key player in the interaction between this ligand and the
16KLVFFAE22 peptide.
Comparing the secondary structure and energies of the interaction of the 16KLVFFAE22
peptide with the second ligand to those for the interaction between 30AIIGLM35 and
the second ligand, the charged residues of the 16KLVFFAE22 Aβ fragment seem to
be of importance for the peptide-peptide interactions.
The change of hydrogen bond energies between the 16KLVFFAE22 peptides suggest
a competition for hydrogen bonds as a mechanism contributing to inhibition. This
is a possible explanation for the observed change in secondary structure.
One might speculate that the growth of 16KLVFFAE22 into a steric zippers is in-
hibited at least by the second ligand. Here peptide-ligand interactions disrupt the
secondary structure. This does not have an effect on the aggregation of oligomers
as small as dodecamers but might prevent formation of fibrils.
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4.2. Outlook
To verify the change in interactions (i.e. coulomb and hydrogen bonds) between
the second ligand and the 16KLVFFAE22 peptide more statistics is needed. There-
fore, additional simulations should be carried out with the 16KLVFFAE22 peptide
together with (i) the second ligand and maybe also with (ii) the first ligand, in the
same setup as before.
It might be that careful evaluation of the already available simulations with 16KLVFFAE22
and the second ligand in a ratio of 12:1 reveal additional information on the ana-
lyzed observables (e.g. hydrogen bonds, interaction energy) to confirm systematic
changes of hydrogen bond and coulomb energies.
To reveal if peptide-ligand interactions (i.e. coulomb and hydrogen bonds) are strong
enough to disassemble preformed structures, the simulations with preformed struc-
tures of 16KLVFFA21 and the added second ligand (not described extensively here)
should be prolonged. As a control the simulation without the ligands also would
need to be prolonged to the same time.
As coulomb interactions seem to be key in the peptide-ligand interactions of 16KLVFFAE22
and the second ligand, electrostatic properties of the system could be changed to test
this hypothesis. Therefore, a possible idea is to apply an additional charge to the
second ligand, thereby giving it a neutral net charge. Another possibility would be
to change the ion concentration of the system. Increased ion concentration should
lead to a decrease of long range coulomb interaction due to shielding effects.
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